ウェスト症候群治療薬の世界市場:疫学予測

◆英語タイトル:West Syndrome - Epidemiology Forecast - 2030
◆商品コード:DELV20JU229
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年6月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(229名様閲覧)USD3,750 ⇒換算¥393,750見積依頼/購入/質問フォーム
Three UserUSD5,625 ⇒換算¥590,625見積依頼/購入/質問フォーム
Site LicenseUSD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s ‘West Syndrome – Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted West Syndrome epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2017–2030

West Syndrome Understanding
West syndrome is an age-related specific epileptic encephalopathy due to multiple and diverse causes. It is characterized by a unique type of seizure called epileptic (infantile) spasms and gross EEG abnormalities of hypsarrhythmia. Usually, West syndrome consists of a characteristic triad: infantile spasms, the arrest of psychomotor development, and hypsarrhythmia, although one element may be missing. Spasms may be flexor, extensor, lightning, or nods, but most commonly they are mixed. Onset peaks are observed between the ages of 4–7 months and always occur before the age of 1 year. Also, boys are more commonly affected, and the prognosis is generally poor.

West syndrome may be separated into two groups: the symptomatic group, which is characterized by previous existence of brain damage signs (psychomotor retardation, neurologic signs, radiologic signs, or other types of seizures) or by a known etiology, and the smaller, cryptogenic group that is characterized by a lack of previous signs of brain damage and known etiology. The prognosis appears to be partly based on early therapy with adrenocorticotropic hormone or oral steroids. Besides, the ILAE new diagnostic scheme classifies West syndrome amongst ‘epileptic encephalopathies’ and prefers ‘epileptic spasms’ rather than ‘infantile spasms’.

It is a constellation of symptoms which are characterized by epileptic or infantile spasms, abnormal pattern of brain waves called hypsarrhythmia, and mental disability. The spasms that occur may range from violent jack-knife or “salaam” movements where the entire body bends in half, or they may change as little as a slight twitching of the shoulder or eye. These spasms usually start in the early months after birth, and medication can sometimes be used to help. They can also occur in elderly patients; they are called “epileptic spasms” rather than infantile spasms if this occurs.

West Syndrome Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Population of West Syndrome, Diagnosed Prevalent Population of west Syndrome and Gender-specific Diagnosed Prevalence of West Syndrome in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

West Syndrome Detailed Epidemiology Segmentation
The total diagnosed prevalent population of West Syndrome in the 7 major markets was found to be 8,057 in 2017.
In the United States, the diagnosed prevalent cases of West Syndrome was found to be 3,999 in 2017.
Delvelnsight has also analyzed gender-specific data for West Syndrome, which clearly suggests that it is more prevalent among males than females. It was found that in the United States the number of cases of West Syndrome in males and females were 2,399 and 1,600 respectively in 2017.
In the EU5 countries the diagnosed prevalence of West Syndrome was found to be maximum in France with 737 cases, followed by the United Kingdom with 684 cases in 2017. While, the least number of cases were found in Spain, with 445 cases in 2017.
In Japan, the diagnosed prevalence of West Syndrome was found to be 1,090 in 2017.
Scope of the Report
The report covers the descriptive overview of West Syndrome, explaining its causes, signs and symptoms, pathophysiology.
The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
The report assesses the disease risk and burden and highlights the unmet needs of West Syndrome.
The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of West Syndrome, Total Diagnosed and Treated Cases of West Syndrome.
Report Highlights
Eleven Year Forecast of West Syndrome
7MM Coverage
Diagnosed Prevalent Population of West Syndrome
Report also covers Gender-specific diagnosed prevalence of West Syndrome, which clearly remarks a male preponderance and this finding maintains the hypothesis that male sex is a risk factor.
Expected launch of a potential therapies, Cannabidiol (CBD) oral solution (INSYS Therapeutics) and Epidiolex (GW Pharmaceuticals), may increase the market size in the coming years, assisted by an increase in diagnosed prevalent population of West Syndrome.
Key Questions Answered
What is the disease risk, burden and unmet needs of West Syndrome?
What is the historical West Syndrome patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
What would be the forecasted patient pool of West Syndrome at the 7MM level?
What will be the growth opportunities across the 7MM with respect to the patient population pertaining to West Syndrome?
Out of the above-mentioned countries, which country would have the highest prevalent population of West Syndrome during the forecast period (2020–2030)?
At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?
Reasons to buy
The West Syndrome report will allow the user to -

Develop business strategies by understanding the trends shaping and driving the 7MM West Syndrome market.
Quantify patient share distribution in the 7MM for West Syndrome.
The West Syndrome epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
The West Syndrome epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.
Key Assessments
Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

【レポートの目次】

1 Key Insights

2 West Syndrome Overview at a Glance

3 Executive Summary of West Syndrome

4 West Syndrome: Disease Background and Overview

4.1 Introduction

4.2 Metabolic etiologies in West syndrome

4.3 Etiology-specific Subtypes of West syndrome

4.4 Causes and Risk Factors

4.5 Clinical Manifestations

4.6 Symptoms

4.7 Pathophysiology

4.8 Diagnosis

4.9 Differential Diagnosis

4.10 Prognosis

5 Diagnostic Algorithm for West Syndrome

6 Clinical Algorithm for Epileptic Spasms (Infantile Spasms) By Texas Children’s Hospital

7 Epidemiology and Patient Population

7.1 Key Findings

7.2 7MM Total Prevalent Population of West Syndrome

7.3 7MM Total Diagnosed Prevalent Population of West Syndrome

8 Country Wise-Epidemiology of West Syndrome

8.1 Assumptions and Rationale: 7MM Countries

8.2 United States

8.2.1 Assumptions and Rationale

8.2.2 Total Prevalent Population of West Syndrome in the United States

8.2.3 Total Diagnosed Prevalent Population of West Syndrome in the United States

8.2.4 Gender-specific Diagnosed Prevalent Population of West Syndrome in the United States

8.3 EU5 Countries

8.3.1 Assumptions and Rationale

8.4 Germany

8.4.1 Total Prevalent Population of West Syndrome in Germany

8.4.2 Total Diagnosed Prevalent Population of West Syndrome in Germany

8.4.3 Gender-specific Diagnosed Prevalent Population of West Syndrome in Germany

8.5 France

8.5.1 Total Prevalent Population of West Syndrome in France

8.5.2 Total Diagnosed Prevalent Population of West Syndrome in France

8.5.3 Gender-specific Diagnosed Prevalent Population of West Syndrome in France

8.6 Italy

8.6.1 Total Prevalent Population of West Syndrome in Italy

8.6.2 Total Diagnosed Prevalent Population of West Syndrome in Italy

8.6.3 Gender-specific Diagnosed Prevalent Population of West Syndrome in Italy

8.7 Spain

8.7.1 Total Prevalent Population of West Syndrome in Spain

8.7.2 Total Diagnosed Prevalent Population of West Syndrome in Spain

8.7.3 Gender-specific Diagnosed Prevalent Population of West Syndrome in Spain

8.8 United Kingdom

8.8.1 Total Prevalent Population of West Syndrome in the United Kingdom

8.8.2 Total Diagnosed Prevalent Population of West Syndrome in the United Kingdom

8.8.3 Gender-specific Diagnosed Prevalent Population of West Syndrome in the United Kingdom

8.9 Japan

8.9.1 Assumptions and Rationale

8.9.2 Total Prevalent Population of West Syndrome in Japan

8.9.3 Total Diagnosed Prevalent Population of West Syndrome in Japan

8.9.4 Gender-specific Diagnosed Prevalent Population of West Syndrome in Japan

9 Appendix

9.1 Bibliography

9.2 Report Methodology

10 DelveInsight Capabilities

11 Disclaimer

12 About DelveInsight

Table 1: Summary of West Syndrome, Epidemiology and Key Events (2017–2030)

Table 2: Metabolic etiologies in Infantile Spasms

Table 3: Proportion of occurrence of different symptoms in West Syndrome patients

Table 4: Examinations to be conducted for West Syndrome

Table 5: Differential Diagnosis for Infantile spasms

Table 6: Total Prevalent Population of West Syndrome in the 7MM (2017–2030)

Table 7: Total Diagnosed Prevalent Population of West Syndrome in the 7MM (2017–2030)

Table 8: Total Prevalent Population of West Syndrome in the United States (2017–2030)

Table 9: Total Diagnosed Prevalent Population of West Syndrome in the United States (2017–2030)

Table 10: Gender-specific Diagnosed Prevalent Population of West Syndrome in the United States (2017–2030)

Table 11: Total Prevalent Population of West Syndrome in Germany (2017–2030)

Table 12: Total Diagnosed Prevalent Population of West Syndrome in Germany (2017–2030)

Table 13: Gender-specific Diagnosed Prevalent Population of West Syndrome in Germany (2017–2030)

Table 14: Total Prevalent Population of West Syndrome in France (2017–2030)

Table 15: Total Diagnosed Prevalent Population of West Syndrome in France (2017–2030)

Table 16: Gender-specific Diagnosed Prevalent Population of West Syndrome in France (2017–2030)

Table 17: Total Prevalent Population of West Syndrome in Italy (2017–2030)

Table 18: Total Diagnosed Prevalent Population of West Syndrome in Italy (2017–2030)

Table 19: Gender-specific Diagnosed Prevalent Population of West Syndrome in Italy (2017–2030)

Table 20: Total Prevalent Population of West Syndrome in Spain (2017–2030)

Table 21: Total Diagnosed Prevalent Population of West Syndrome in Spain (2017–2030)

Table 22: Gender-specific Diagnosed Prevalent Population of West Syndrome in Spain (2017–2030)

Table 23: Total Prevalent Population of West Syndrome in the United Kingdom (2017–2030)

Table 24: Total Diagnosed Prevalent Population of West Syndrome in the United Kingdom (2017–2030)

Table 25: Gender-specific Diagnosed Prevalent Population of West Syndrome in the United Kingdom (2017–2030)

Table 26: Total Prevalent Population of West Syndrome in the Japan (2017–2030)

Table 27: Total Diagnosed Prevalent Population of West Syndrome in Japan (2017–2030)

Table 28: Gender-specific Diagnosed Prevalent Population of West Syndrome in Japan (2017–2030)



List of Figures:

Figure 1: Key Causes of West Syndrome

Figure 2: Symptoms of West Syndrome

Figure 3: Main characteristic symptoms of West Syndrome

Figure 4: Diagnostic Algorithm for West Syndrome

Figure 5: Clinical Algorithm for Epileptic Spasms (Infantile Spasms)

Figure 6: Total Prevalent Population of West Syndrome in the 7MM (2017–2030)

Figure 7: Total Diagnosed Prevalent Population of West Syndrome in the 7MM (2017–2030)

Figure 8: Total Prevalent Population of West Syndrome in the United States (2017–2030)

Figure 9: Total Diagnosed Prevalent Population of West Syndrome in the United States (2017–2030)

Figure 10: Gender-specific Diagnosed Prevalent Population of West Syndrome in the US (2017–2030)

Figure 11: Total Prevalent Population of West Syndrome in Germany (2017–2030)

Figure 12: Total Diagnosed Prevalent Population of West Syndrome in Germany (2017–2030)

Figure 13: Gender-specific Diagnosed Prevalent Population of West Syndrome in Germany (2017–2030)

Figure 14: Total Prevalent Population of West Syndrome in France (2017–2030)

Figure 15: Total Diagnosed Prevalent Population of West Syndrome in France (2017–2030)

Figure 16: Gender-specific Diagnosed Prevalent Population of West Syndrome in France (2017–2030)

Figure 17: Total Prevalent Population of West Syndrome in Italy (2017–2030)

Figure 18: Total Diagnosed Prevalent Population of West Syndrome in Italy (2017–2030)

Figure 19: Gender-specific Diagnosed Prevalent Population of West Syndrome in Italy (2017–2030)

Figure 20: Total Prevalent Population of West Syndrome in Spain (2017–2030)

Figure 21: Total Diagnosed Prevalent Population of West Syndrome in Spain (2017–2030)

Figure 22: Gender-specific Diagnosed Prevalent Population of West Syndrome in Spain (2017–2030)

Figure 23: Total Prevalent Population of West Syndrome in the United Kingdom (2017–2030)

Figure 24: Total Diagnosed Prevalent Population of West Syndrome in the United Kingdom (2017–2030)

Figure 25: Gender-specific Diagnosed Prevalent Population of West Syndrome in the UK (2017–2030)

Figure 26: Total Prevalent Population of West Syndrome in Japan (2017–2030)

Figure 27: Total Diagnosed Prevalent Population of West Syndrome in Japan (2017–2030)

Figure 28: Gender-specific Diagnosed Prevalent Population of West Syndrome in Japan (2017–2030)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ウェスト症候群治療薬の世界市場:疫学予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆